Thermo Fisher Scientific Q1 Earnings Surpass Estimates, CEO Touts 'Strong Performance' Despite Economic Uncertainty

Core Viewpoint - Thermo Fisher Scientific Inc. reported strong first-quarter 2025 results, with adjusted earnings per share of $5.15, surpassing analyst expectations of$5.10, and quarterly sales of $10.36 billion, slightly above the consensus estimate of$10.23 billion [1][2] Financial Performance - Adjusted operating income for Q1 2025 was $2.27 billion, a slight decrease from$2.28 billion in the same quarter last year [3] - Adjusted operating margin was 21.9%, down from 22% in Q1 2024 [3] - Organic revenue growth was recorded at 1% [1] Segment Performance - Life Sciences Solutions Segment revenue increased by 2.5% year over year to $2.34 billion [3] - Analytical Instruments Segment sales rose by 1.8$1.72 billion [3] - Specialty Diagnostics Segment revenues grew by 3.5% to $1.15 billion [4] - Laboratory Products and Biopharma Services segment sales decreased by 1.5$5.64 billion [4] Strategic Developments - The company announced an agreement to acquire Solventum's SOLV Purification & Filtration business for approximately $4.1 billion in cash, which focuses on purification and filtration technologies for biologics and medical technologies [4] Market Reaction - Following the earnings report, Thermo Fisher's stock price increased by 4.23$453.10 [5]